Compare INCY & VRSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCY | VRSK |
|---|---|---|
| Founded | 1991 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 26.4B |
| IPO Year | 1994 | 2008 |
| Metric | INCY | VRSK |
|---|---|---|
| Price | $114.90 | $203.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 20 |
| Target Price | $132.17 | ★ $234.25 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | ★ 4173.33 | N/A |
| EPS | 0.50 | ★ 5.18 |
| Revenue | ★ $3,394,635,000.00 | N/A |
| Revenue This Year | $17.74 | $4.72 |
| Revenue Next Year | $4.38 | $6.77 |
| P/E Ratio | $231.80 | ★ $38.71 |
| Revenue Growth | ★ 13.67 | N/A |
| 52 Week Low | $89.25 | $155.94 |
| 52 Week High | $132.60 | $227.16 |
| Indicator | INCY | VRSK |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 55.06 |
| Support Level | $109.78 | $197.59 |
| Resistance Level | $119.29 | $204.95 |
| Average True Range (ATR) | 3.73 | 6.77 |
| MACD | -0.53 | -0.97 |
| Stochastic Oscillator | 3.94 | 41.22 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Verisk is a leading data, analytics, and technology provider for property-casualty insurers. Verisk traces its history to Insurance Services Office, a nonprofit advisory organization founded in 1971 by US P&C insurers. ISO was formed as an association of insurance companies to assist with a variety of insurance use cases, such as reporting to regulators, defining policies, and determining independent premium rates. As the firm expanded its use cases, it became a for-profit company, renamed Verisk, and went public in 2009.Verisk's single segment (insurance) provides underwriting solutions, including forms, rules, loss costs, and catastrophe modeling. For claims, Verisk's solutions include property repair estimates and antifraud tools. About 83% of Verisk's revenue is US-based.